26 Mar 2018 15:30
The following amendment has been made to the "Director/PDMR Shareholding" announcement released earlier today under RNS no. 9247I.
In the Company's issued share capital table, the original 'Resulting number of Ordinary Shares held" stated 10,451,172, which has been corrected as follows: 10,445,172.
All other details remain unchanged. The full amended text is shown below.
Horizon Discovery Group plc
Director/PDMR Shareholding
Cambridge, UK, 26 March 2018: Horizon Discovery Group plc (LSE: HZD) ("Horizon" or the "Company"), a global leader in the application of gene editing and gene modulation to deliver inspired cell solutions, today announces that Dr Jonathan Milner, a Non-Executive Director of the Company, has purchased certain ordinary shares of 1.0p each in the capital of the Company ("Ordinary Shares"). Details of this purchase of Ordinary Shares, and Dr Milner's resulting beneficial interest in the Company's issued share capital, are shown below:
Name of Director | Number of Ordinary Shares purchased | Average purchase price per share (pence) | Resulting number of Ordinary Shares held | Resulting number of Ordinary Shares held as a percentage of the Company's issued share capital |
Dr Jonathan Milner* | 304,000 | 161.7 | 10,445,172 | 7.0% |
*Mr Milner's purchase of Ordinary Shares was made by his wife (Mrs Roza Gounari) and is therefore considered a beneficial holding of Mr Milner's.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1 | Details of the person discharging managerial responsibilities/person closely associated | ||
a) | Name | Dr Jonathan Milner | |
2 | Reason for the notification | ||
a) | Position/status | Non-Executive Director | |
b) | Initial notification /Amendment | Initial Notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Horizon Discovery Group plc | |
b) | Legal Entity Identifier | 213800L812B9NI5M3G89 | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument
Identification code | Ordinary shares of 1.0p each
GB00BK8FL363 | |
b) | Nature of the transaction | Purchase of shares
| |
c) | Currency | GBP | |
d) | Price(s) and volume(s) | Average Price(s) | Volume(s) |
161.7p | 304,000 | ||
e) | Aggregated information - Aggregated volume - Price - Aggregated total |
304,000 161.7p £491,710 | |
f) | Date of the transaction | 26 March 2018 | |
g) | Place of the transaction | London Stock Exchange, AIM | |
- ENDS -
For further information from Horizon Discovery Group plc, please contact:
Horizon Discovery Group plc
Richard Vellacott, Interim Chief Executive Officer and Chief Financial Officer
Chris Claxton, Investor Relations Officer
Tel: +44 (0) 1223 655 580
Consilium Strategic Communications (Financial Media and Investor Relations)
Mary-Jane Elliott / Matthew Neal / Melissa Gardiner
Tel: +44 (0) 20 3709 5701
Email: horizon@consilium-comms.com
Numis Securities Limited (Broker and NOMAD)
Michael Meade / Freddie Barnfield
Tel: +44 (0) 207 260 1000
About Horizon Discovery Group plc www.horizondiscovery.com
Horizon Discovery Group plc (LSE: HZD) ("Horizon") is a world leader in gene editing and gene modulation technologies. Horizon delivers inspired cell solutions using its translational genomics platform, a highly precise and flexible suite of DNA editing (rAAV, ZFN, CRISPR and Transposon) and modulation (RNAi, cDNA and ORF) tools for research and clinical applications that advance human health. Horizon's platforms and capabilities enable researchers to alter almost any gene or modulate its function in human or mammalian cell lines.
Horizon offers an extensive range of catalogue products and related research services to support a greater understanding of the function of genes across all species and the genetic drivers of human disease and the development of personalized molecular, cell and gene therapies. These have been adopted by over 10,000 academic, drug discovery, drug manufacturing and clinical diagnostics customers around the globe, as well as in the Company's own R&D pipeline.
Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange's AIM market under the ticker "HZD".